Sonam Ruit
Podiatrist · York, PANPI 1730112186
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $4,146 of the $6,598 with a category attached, or 62.8%. Stryker accounts for 69.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $2,509 and has fallen 87.1% since, to $324 in 2025.
Across 113 payments — averaging $58.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$5K
- Organogenesis Inc.$941
- Arthrex$455
- Novus Surgical Consultants$317
- Treace Medical Concepts, Inc.$85
- Inari Medical, Inc.$53
- plus $148 from 7 others
What the payments were for
- Travel & lodging$4,14663%
- Food & beverage$2,45237%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 31 | $4,599 |
| Organogenesis Inc. | 61 | $941 |
| Arthrex | 2 | $455 |
| Novus Surgical Consultants | 6 | $317 |
| Treace Medical Concepts, Inc. | 3 | $85 |
| Inari Medical, Inc. | 1 | $53 |
| Zyla Life Sciences, Inc. | 3 | $40 |
| Acell, Inc. | 1 | $23 |
| KCI USA, Inc. | 1 | $20 |
| Kerecis Limited | 1 | $20 |
| Checkpoint Surgical, Inc | 1 | $18 |
| Biocomposites Inc | 1 | $14 |
| Integra Lifesciences Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,598 in reported general payments places this provider in the 85th percentile of 445 podiatrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 16 | $5,350 |
| EliquisApixaban | 18 | $5,156 |
| Gabapentin | 77 | $1,675 |
| Celecoxib | 21 | $1,167 |
| Triamcinolone Acetonide | 16 | $284 |
| Cephalexin | 39 | $200 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 27 | $170 |
| Doxycycline Hyclate | 21 | $151 |
| Methylprednisolone | 24 | $144 |
| Oxycodone Hcl | 45 | $126 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $49 |
| Meloxicam | 30 | $37 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in York
- John LapelusaYork$54K
- Samuel ClellenYork$29K
- Rachel WarnerYork$26K
- Rahim LakhaniYork$21K
- Michael FalciYork$9K
- Mark HofbauerBelle Vernon$1.1M
- Daniel PerezPhiladelphia$434K
- Christopher BarrettChester$229K
- Alan CatanzaritiPittsburgh$80K
- John StarinskiPen Argyl$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.